Delivery vehicles comprising stable lipid/nucleic acid complexes
OwnerSean M. Sullivan, Hans Hoflandinventors
Life of this patent
Estimating the term…
Abstract
Stable polynucleotide delivery vehicles (SPDVs) are described which incorporate a polynucleotide/cationic lipid complex as structural components of the SPDV. The subject SPDVs may optionally incorporate synthetic biodegradable amphipathic lipids, and suitable targeting agents.
Claims28
A stable synthetic polynucleotide delivery vehicle comprising an amphipathic cationic lipid conjugate.
A stable synthetic polynucleotide delivery vehicle comprising a biodegradable amphipathic cationic lipid conjugate.
A process for making a stable polynucleotide delivery vehicle, comprising:
- a) contacting the polynucleotide with a amphipathic cationic lipid conjugate in the presence of a detergent;
- and
- b) removing the detergent to form a polynucleotide and cationic lipid complex.
A biocompatible amphipathic cationic lipid conjugate having the general formula:
- R1-X-R2
- wherein R1 is a biodegradable lipid moiety;
- R2 is a biocompatible cationic or polycationic moiety;
- and
- X is a biocompatible and labile covalent linker.
The use of a stable polynucleotide delivery vehicle to deliver a polynucleotide of interest to a cell.
A stable synthetic polynucleotide delivery vehicle of reduced toxicity.
A process for making a stable polynucleotide delivery vehicle, comprising:
- a) contacting the polynucleotide with a amphipathic cationic lipid conjugate in the presence of a cation and detergent;
- and
- b) removing the detergent to form a polynucleotide and cationic lipid complex.
Dependencies are inferred from the claim text.